Sumitomo Pharma
¥1,613.50Change from previous close: −1.31%Absolute change: −¥21.50
Valuation
Data as of October 3, 2026
Valuation multiples
- Market cap
- ¥723.81B
- Enterprise value
- ¥807.82B
- P/E (trailing 12 months)
- 6.00
- Forward P/E
- 94.2
- PEG
- 1.93
- Price/book
- 1.77
- Price/sales
- 1.52
- EV/EBITDA
- 11.8
- EV/revenue
- 1.70
Profitability and growth
- Gross margin
- 55.0%
- Operating margin
- 13.7%
- Net margin
- 23.7%
- ROE
- 38.5%
- ROA
- 3.9%
- Revenue growth (year over year)
- 19.9%
- Earnings growth (year over year)
- 38.3%
Financial health
- Total cash
- ¥76.64B
- Total debt
- ¥160.66B
- Debt/equity
- 0.39
- Current ratio
- 1.21
- Quick ratio
- 0.84
Dividends
- Payout ratio
- 0.0%
- Ex-dividend date
- March 30, 2023
Analysts and estimates
- Average price target
- ¥2,114.29
- Median price target
- ¥2,000.00
- High price target
- ¥2,700.00
- Low price target
- ¥1,500.00
- Analysts with a price target
- 7
- Consensus
- Buy
- Forward EPS
- ¥17.13
- EPS estimate, current year
- ¥215.16
Shares and trading
- Beta
- 0.48
- Average volume
- 3.73M
- Shares outstanding
- 448.59M
- Float
- 238.43M
- Institutional ownership
- 21.5%
- Insider ownership
- 48.8%